Eisai to Use BioSeek's Drug Modeling Platform | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Asterand subsidiary BioSeek will collaborate on multiple oncology and inflammation-focused projects with the Japanese pharmaceutical company Eisai, Asterand said today.

Under the two-year agreement, the BioMap platform, which includes cell-based models designed to replicate interactions that are found in pharmacology and toxicology, will be used in research projects in both the US and Japan.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.